Price T Rowe Associates Inc Vertex Pharmaceuticals Inc Transaction History

Price T Rowe Associates Inc

$812 Billion
Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,917,227 shares of VRTX stock, worth $1.27 Billion. This represents 0.17% of its overall portfolio holdings.

Number of Shares

2,917,227

Previous 1,690,700 72.55%

Holding current value

$1.27 Billion

Previous $681 Million 107.73%

% of portfolio

0.17%

Previous 0.08%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$402.49 - $513.76 $494 Million - $630 Million	1,226,527 Added 72.55%	2,917,227 $1.41 Billion
Q4 2024 Feb 14, 2025	SELL	$396.64 - $516.74 $30.7 Million - $39.9 Million	-77,310 Reduced 4.37%	1,690,700 $681 Million
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $204 Million - $224 Million	-443,664 Reduced 20.06%	1,768,010 $822 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $896 Million - $1.11 Billion	-2,281,748 Reduced 50.78%	2,211,674 $1.04 Billion
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $568 Million - $622 Million	-1,393,990 Reduced 23.68%	4,493,422 $1.88 Billion
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $330 Million - $395 Million	-962,654 Reduced 14.05%	5,887,412 $2.4 Billion
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $30.9 Million - $33.1 Million	91,308 Added 1.35%	6,850,066 $2.38 Billion
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $53 Million - $59.3 Million	168,568 Added 2.56%	6,758,758 $2.38 Billion
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $536 Million - $611 Million	1,892,523 Added 40.29%	6,590,190 $2.08 Billion
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $132 Million - $148 Million	-460,287 Reduced 8.92%	4,697,667 $1.36 Billion
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $53.5 Million - $59.7 Million	195,271 Added 3.93%	5,157,954 $1.49 Billion
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $80.4 Million - $100 Million	-342,014 Reduced 6.45%	4,962,683 $1.4 Billion
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $25.8 Million - $30.4 Million	-116,594 Reduced 2.15%	5,304,697 $1.38 Billion
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $49 Million - $61.9 Million	-276,956 Reduced 4.86%	5,421,291 $1.19 Billion
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $1.34 Billion - $1.5 Billion	-7,400,245 Reduced 56.5%	5,698,247 $1.03 Billion
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $647 Million - $763 Million	-3,451,384 Reduced 20.85%	13,098,492 $2.64 Billion
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $637 Million - $743 Million	-3,077,048 Reduced 15.68%	16,549,876 $3.56 Billion
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $4.06 Billion - $5.42 Billion	19,626,924 New	19,626,924 $4.63 Billion

Others Institutions Holding VRTX

# of Institutions

1,830

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $112B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Vertex Pharmaceuticals Inc Transaction History